boceprevir

Merck’s Cavalier Attitude Towards the Welfare of HIV/HCV Coinfected Patients

What You Don’t Know, You Can Selltagline Spring 2012<https://www.treatmentactiongroup.org/tagline/2012/spring/tagline/2012/spring>by Tracy SwanIn places where access to antiretroviral therapy is widespread, peopleliving with HIV are now dying from a common and curable coinfection:hepatitis C virus (HCV). HIV increases the risk for, and accelerates therate of, liver disease from hepatitis C. Pegylated interferon andribavirin, medications used to treat …

Merck’s Cavalier Attitude Towards the Welfare of HIV/HCV Coinfected Patients Read More »

THE FAIR PRICING COALITION EXPRESSES DISMAY AT THE PRICE OF MERCK’S NEWLY APPROVED HEPATITIS C DRUG

May 17, 2011—On May 13, 2011, the FDA approved Merck’s Victrelis (boceprevir), the first new drug for the treatment of hepatitis C virus (HCV) infection to come to market in almost ten years. The United States Department of Health and Human Services estimates that there are between 2.7 to 3.9 million people in the United …

THE FAIR PRICING COALITION EXPRESSES DISMAY AT THE PRICE OF MERCK’S NEWLY APPROVED HEPATITIS C DRUG Read More »